New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival.
from Latest Science News -- ScienceDaily http://bit.ly/2x9t52T
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment